EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The natural mutation Arg221aTrp in human α-thrombin abrogates physiological Na+ binding and preferentially hinders the protease anticoagulant functions

Laura Acquasaliente, Andrea Pierangelini, Federico Uliana, Anna Pagotto, Alberto Covallero, Daniele Peterle, Serena Toffanin, Cristiana Bulato, Elena Campello, Antonella Ciancetta, Paolo Simioni, Vincenzo De Filippis

Journal of Thrombosis and Haemostasis · 2026

DOI: 10.1016/j.jtha.2026.06.033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026. Verfasst von Laura Acquasaliente und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Protein Chemistry, Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy. Hauptthemen laut MEDLINE: Mutation, Blood Coagulation, Thrombin, Sodium. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foundation of the Savings Bank of Padua and Rovigo, Government of Italy Ministry of Education University and Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Natural mutations in the prothrombin gene, involving the substitution of Arg596 with polar/apolar amino acids, represent an important risk factor for thrombosis. Notably, Arg596 in prothrombin corresponds to position 221a in the Na+-binding loop of mature α-thrombin (αT). Patients carrying these mutations (Arg221a→Gln/Leu/Trp) share a common clinical phenotype, characterized by a moderately reduced procoagulant function in coagulation tests and resistance of αT variants to inactivation by antithrombin III (ATIII). However, the biochemical mechanisms linking these mutations to the increased thrombotic risk remain elusive. OBJECTIVES: To provide quantitative data on the effect that the recombinant Arg221aTrp αT mutant (αT-PD2) has on the activation of procoagulant and anticoagulant pathways and elucidate the structural basis of the observed functional changes. METHODS: A multipronged approach was used, integrating recombinant DNA techniques, clotting/fibrinolytic and enzymatic assays, microscopy, proteomics, spectroscopic, mass spectrometry, and molecular modeling techniques. RESULTS: Arg221aTrp mutation abrogates physiological Na+ binding and reduces the proportion of the fully active αT conformation. αT-PD2 affects procoagulant pathways by less efficiently generating fibrin (7-fold) and activating platelets (10-fold). The mutation potently affects anticoagulant pathways, as αT-PD2 is less efficiently inhibited by ATIII (3-fold), binds heparin less tightly (10-fold), and much less efficiently (41-fold) activates protein C. CONCLUSION: Our data indicate that the procoagulant phenotype, observed in Arg221aTrp mutation carriers, may result from opposing inhibitory effects on both procoagulant and anticoagulant pathways, with the impact on anticoagulant pathways being predominant and shifting the natural anticoagulant↔procoagulant equilibrium in vivo toward thrombosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MutationBlood CoagulationThrombinSodiumProthrombinAnticoagulantsHumansProtein BindingPhenotypeProtein ConformationModels, MolecularArginineAntithrombin IIIThrombosisRecombinant ProteinsBinding Sites

Stichwörter der Autor:innen

antithrombingenetic mutationsnatural thrombin variantsthrombophiliavenous thromboembolism

Substanzen

ThrombinSodiumProthrombinAnticoagulantsArginineAntithrombin IIIRecombinant Proteins

Autor:innen und Institutionen

  • Laboratory of Protein Chemistry, Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
  • Department of Biology, Institute of Biochemistry, ETH Zürich, Zürich, Switzerland.
  • First Chair of Internal Medicine and Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine, University Hospital of Padua, Padua, Italy.
  • Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Ferrara, Italy.
  • First Chair of Internal Medicine and Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine, University Hospital of Padua, Padua, Italy. Electronic address: paolo.simioni@unipd.it.
  • Laboratory of Protein Chemistry, Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy. Electronic address: vincenzo.defilippis@unipd.it.

Förderung

  • Foundation of the Savings Bank of Padua and Rovigo
  • Government of Italy Ministry of Education University and Research

Zitieren

APA

Acquasaliente, L., Pierangelini, A., Uliana, F., Pagotto, A., Covallero, A., Peterle, D., Toffanin, S., Bulato, C., Campello, E., Ciancetta, A., Simioni, P., & De Filippis, V. (2026). The natural mutation Arg221aTrp in human α-thrombin abrogates physiological Na+ binding and preferentially hinders the protease anticoagulant functions. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2026.06.033

Vancouver

Acquasaliente L, Pierangelini A, Uliana F, Pagotto A, Covallero A, Peterle D, et al. The natural mutation Arg221aTrp in human α-thrombin abrogates physiological Na+ binding and preferentially hinders the protease anticoagulant functions. Journal of Thrombosis and Haemostasis. 2026. doi:10.1016/j.jtha.2026.06.033

BibTeX
@article{Acquasaliente2026,
  author = {Acquasaliente, Laura and Pierangelini, Andrea and Uliana, Federico and Pagotto, Anna and Covallero, Alberto and Peterle, Daniele and Toffanin, Serena and Bulato, Cristiana and Campello, Elena and Ciancetta, Antonella and Simioni, Paolo and De Filippis, Vincenzo},
  title = {The natural mutation Arg221aTrp in human α-thrombin abrogates physiological Na+ binding and preferentially hinders the protease anticoagulant functions},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2026},
  doi = {10.1016/j.jtha.2026.06.033}
}
Kostenlos starten →